共 96 条
[1]
Bartalena L(2009)Clinical practice Graves’ ophthalmopathy N Engl J Med 360 994-1001
[2]
Tanda ML(2016)The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy Eur Thyroid J 5 9-26
[3]
Bartalena L(2019)Immunotherapies for thyroid eye disease Curr Opin Endocrinol Diabetes Obes 26 250-255
[4]
Baldeschi L(2019)Can combination of glucocorticoids with other immunosuppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 42 351-352
[5]
Boboridis K(2019)Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy? Eur J Endocrinol 181 D27-D43
[6]
Eckstein A(2017)Teprotumumab for thyroid-associated ophthalmopathy N Engl J Med 376 1748-1761
[7]
Kahaly GJ(2017)Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 40 885-887
[8]
Marcocci C(2020)Teprotumumab for the treatment of active thyroid eye disease N Engl J Med 382 341-352
[9]
Perros P(2012)Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy J Clin Endocrinol Metab 97 4454-4463
[10]
Salvi M(2012)Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study Eur J Endocrinol 172 269-276